[PDF][PDF] Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
PC Fong, TA Yap, DS Boss, CP Carden… - Journal of clinical …, 2010 - researchgate.net
Journal of clinical oncology, 2010•researchgate.net
Purpose Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy
using poly (ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers
in whom tumor cells have defective homologous recombination (HR) DNA repair. Platinum-
based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent,
oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation
carriers.
using poly (ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers
in whom tumor cells have defective homologous recombination (HR) DNA repair. Platinum-
based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent,
oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation
carriers.
Purpose
Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly (ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair. Platinum-based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers.
researchgate.net